Raphael Pharmaceutical (RAPH) Change in Account Payables (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Change in Account Payables of $291000.0 for Q4 2025, up 171.85% on a YoY basis from $107043.6 in Q4 2024, and up 52.36% sequentially from $191000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Change in Account Payables (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Change in Account Payables data on file, last reported at $291000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Account Payables rose 171.85% year-over-year to $291000.0; the trailing twelve-month figure through Dec 2025 stood at $818000.0 (up 330.53% YoY), and the FY2025 full-year result was $818000.0, up 330.53% from the prior year.
- Change in Account Payables grew to $291000.0 in Q4 2025, from $191000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $421000.0 in Q3 2023 to a low of -$405000.0 in Q4 2024.
- A 5-year average of $51850.0 and a median of $14000.0 in 2021 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables sank 10300.0% in 2023 and surged 831.58% in 2025, its largest moves.
- Tracing RAPH's Change in Account Payables over 5 years: stood at -$127000.0 in 2021, then soared by 53.54% to -$59000.0 in 2022, then slumped by 266.1% to -$216000.0 in 2023, then plunged by 87.5% to -$405000.0 in 2024, then soared by 171.85% to $291000.0 in 2025.
- Business Quant data shows RAPH's Change in Account Payables at $291000.0 in Q4 2025, $191000.0 in Q3 2025, and $278000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 291,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 291,000.00 |
| Dec 31, 2025 | 291,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Sep 30, 2025 | 191,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 278,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | -405,000.00 |
| Dec 31, 2024 | -405,000.00 |
| Sep 30, 2024 | 249,000.00 |
| Sep 30, 2024 | 249,000.00 |
| Jun 30, 2024 | -38,000.00 |
| Jun 30, 2024 | -38,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Mar 31, 2024 | 384,000.00 |
| Dec 31, 2023 | -216,000.00 |
| Dec 31, 2023 | -216,000.00 |
| Sep 30, 2023 | 421,000.00 |
| Sep 30, 2023 | 421,000.00 |